or
forgot password

Patient Assistance to Reduce Breast Cancer Disparities


N/A
18 Years
N/A
Not Enrolling
Female
Early-Stage Breast Cancer

Thank you

Trial Information

Patient Assistance to Reduce Breast Cancer Disparities


Numerous trials proved the efficacy of radiation following breast conserving surgery and
systemic therapies to increase disease-free and overall survival among women with
early-stage breast cancer. Yet 14%-89% of women do not receive them, especially minority
women. Despite lower incidence of the disease, African American women are more likely than
white women to die of breast cancer. As we near racial equity in rates of breast cancer
screening, disparities in treatment and mortality remain. Efforts to achieve control of
breast cancer and reduce racial disparities in mortality will not be fully realized until
proven effective treatments are provided to those who can benefit.

Underuse of effective treatments may be caused by patient, physician and system factors.
For breast cancer screening, women's lack of access to care; insurance; transportation;
beliefs about fatalism and curability, and cancer's effect on partner relationships, all
impact mammography rates. For breast cancer treatment, little is known about
patient-related reasons for underuse, and less is known about racial differences in such
reasons.

Interventions targeted to specific causes are more likely to succeed. For breast cancer
screening, patient-centered interventions that successfully raise mammography rates among
minority women include lay health workers to raise awareness about and address cultural
beliefs and barriers to screening, vouchers to pay for screening and navigators to help
women with abnormal screenings obtain needed follow-up. For breast cancer treatment,
patient-assistance programs provide practical support such as financial counseling, aid with
navigating the complex healthcare system, emotional support, and information about cancer
and its treatment. Such programs abound but patients are often unaware of them. While
these services may increase the receipt of effective adjuvant therapies, these strategies
have not been rigorously tested.

We propose to conduct a randomized controlled trial to evaluate the effectiveness of
patient-assistance programs as compared with usual care on receipt of adjuvant therapies
among minority and nonminority women with newly operated early-stage breast cancer. During
the 24 month trial, we will assess patients' beliefs about cancer and its treatment, and
their practical, psychosocial, and informational needs and barriers to care. We will
identify and train employees in existing cancer assistance services in order to increase the
sustainability of this program beyond the grant-funded cycle. Specifically, we propose:

1. To assess racial differences in early-stage breast cancer patients' experiences,
beliefs about and barriers to effective adjuvant treatments;

2. To evaluate the effectiveness of an intervention connecting women with early-stage
breast cancer and cancer-related needs to community and hospital-based
patient-assistance programs to reduce underuse of effective adjuvant breast cancer
treatment overall and in minority populations and to assess its sustainability; and

3. To evaluate whether this patient assistance intervention affects patients' knowledge,
attitudes and behaviors


Inclusion Criteria:



- All patients, who are English or Spanish speaking, with a new primary stage 1 or 2
breast cancer who have undergone either breast conserving surgery or mastectomy and
those with tumors >1cm or <1cm and poorly differentiated;

- All surgeons performing breast surgery at the participating hospitals

Exclusion Criteria:

- Patients with dementia or those with a poor prognosis due to end-stage organ failure
or other concomitant conditions such as those undergoing treatment for other cancers

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)

Outcome Measure:

initiation and completion of primary treatment

Outcome Time Frame:

Measured after completion of 6-mth interview

Safety Issue:

No

Principal Investigator

Nina A Bickell, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Mount Sinai School of Medicine

Authority:

United States: Institutional Review Board

Study ID:

03-0593

NCT ID:

NCT00233077

Start Date:

October 2006

Completion Date:

January 2011

Related Keywords:

  • Early-Stage Breast Cancer
  • breast cancer
  • adjuvant treatment
  • racial disparities
  • Breast Neoplasms

Name

Location

Albert Einstein College of Medicine Bronx, New York  10461
Mount Sinai School of Medicine New York, New York  10029
Elmhurst Hospital Center Elmhurst, New York  11373
Montefiore Medical Center Bronx, New York  10467-2490
Columbia University New York, New York  10032-3784
Queens Hospital Center Jamaica, New York  11432
Harlem Hospital Center New York, New York  10037
Metropolitan Hospital New York, New York  10029